Great Point Partners’s Puma Biotechnology PBYI Stock Holding History

Great Point Partners’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,486,544	Closed	-$4.85M	–	36
2024 Q2	$4.85M	Buy	1,486,544 +142,916	+11%	+$627K	0.93%	29
2024 Q1	$7.12M	Buy	1,343,628 +250,355	+23%	+$1.35M	1.11%	30
2023 Q4	$4.73M	Buy	+1,093,273	New	+$3.62M	0.81%	28
2021 Q4	–	Sell	-1,300,000	Closed	-$9.11M	–	45
2021 Q3	$9.11M	Hold	1,300,000	–	–	2.12%	19
2021 Q2	$11.9M	Hold	1,300,000	–	–	2.5%	19
2021 Q1	$12.6M	Hold	1,300,000	–	–	2.61%	18
2020 Q4	$13.3M	Buy	1,300,000 +197,927	+18%	+$2M	2.17%	19
2020 Q3	$11.1M	Buy	1,102,073 +1,009,571	+1,091%	+$10.3M	1%	25
2020 Q2	$965K	Buy	+92,502	New	+$957K	0.08%	35
2019 Q2	–	Sell	-900,000	Closed	-$34.9M	–	39
2019 Q1	$34.9M	Sell	900,000 -479,700	-35%	-$14.7M	3.46%	14
2018 Q4	$28.1M	Buy	+1,379,700	New	+$41.4M	3.55%	12
2018 Q2	–	Sell	-500,000	Closed	-$34M	–	41
2018 Q1	$34M	Buy	+500,000	New	+$37.4M	5.05%	9

Other funds holding PBYI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Great Point Partners's PBYI Position: Q3 2024 in Review

Great Point Partners sold out of Puma Biotechnology (PBYI) in Q3 2024, closing a stake of 1,486,544 shares — an estimated $4.85M sold.

Great Point Partners first reported a position in PBYI in Q1 2018 and held it in 12 quarters. The position peaked at $34.9M in Q1 2019. 100 funds tracked by Wall St. Rank hold PBYI as of Q3 2024.

Great Point Partners reported no remaining Puma Biotechnology position as of Q3 2024 after selling out during the quarter.
Great Point Partners sold 1,486,544 Puma Biotechnology shares in Q3 2024, an estimated $4.85M.
Great Point Partners first reported a position in Puma Biotechnology in Q1 2018 and held it in 12 quarters.
Great Point Partners's Puma Biotechnology position peaked at $34.9M in Q1 2019.
100 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.